The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis

With three new and three recently repurposed drugs, treatment of multidrug-resistant tuberculosis (MDR-TB) is more hopeful today than at any time since it emerged in the 1980s and 1990s [1–3]. This optimism contrasts starkly with dismal global treatment success rates of 48–56% as reported by the World Health Organization (WHO) in its annual Global Tuberculosis Reports from 2014 to 2019 [4, 5].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections and tuberculosis Editorials Source Type: research